Biovalence Technologies is a recombinant proteomics biotech that wants to make a positive impact on human and animal lives. RetroMAD1 is one of two novel, well-defined chimeric proteins with anti-viral properties that can be given orally. Proof of concept, animal studies and clinical trials in pets have shown RetroMAD1 to be effective in reducing clinical signs and/or death resulting from viral infections due to CDV, CPV2, FeLV, FIV and FIPV. The company is now generating revenue in the pet healthcare market while saving lives of cats suffering from feline leukemia, feline infectious peritonitis, and puppies from canine parvovirosis. We are touched to continue receiving many cat owners’ and cat shelters’ emails on the positive effect that RetroMAD1 has on their feline family members, thriving with a good quality of life. In humans, the company has generated data against Herpes, Dengue, AIDS and Ebola. It’s now moving rapidly to work on Covid-19 with partners. Scientists have recently discovered that Sars-CoV2 has a mutation close to that of DENV, HIV, EBOV and FIPV that activates the host cell’s furin protease, allowing rapid invasion.